tiprankstipranks
Trending News
More News >

SSY Group Advances SYN045 Tablets to Phase I Clinical Trials

Story Highlights
  • SSY Group Limited focuses on developing chemical drugs for specific health conditions.
  • SYN045 tablets approved for Phase I trials, enhancing dosing precision and clinical application.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
SSY Group Advances SYN045 Tablets to Phase I Clinical Trials

Confident Investing Starts Here:

An update from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited has announced the approval of its SYN045 tablets for Phase I clinical trials by the National Medical Products Administration of China. The approval includes three different specifications, which will enhance the clinical application and dosing precision of the drug. SYN045, a PGI2 receptor agonist, has shown promising results in preclinical studies with good targeting selectivity and safety, marking a significant step forward in the company’s drug development efforts.

More about SSY Group

SSY Group Limited is a company operating in the pharmaceutical industry, focusing on the development of chemical drugs. The company is involved in creating innovative medications, with a particular emphasis on targeting specific health conditions such as pulmonary hypertension.

YTD Price Performance: 2.09%

Technical Sentiment Signal: Buy

Current Market Cap: $1.28B

For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App